[go: up one dir, main page]

Пређи на садржај

MGS-0039

С Википедије, слободне енциклопедије
MGS-0039
IUPAC ime
(1R,2R,3R,5R,6R)-2-amino-3-(3,4-dihlorobenziloksi)-6-fluorobiciklo[3.1.0]heksan-2,6-dikarbokskilna kiselina
Pravni status
Pravni status
  • Nije regulisan
Identifikatori
CAS broj569686-87-9 ДаY
ATC kodNone
PubChemCID 9886034
ChemSpider8061707
Hemijski podaci
FormulaC15H14Cl2NO5
Molarna masa378,179 g/mol
  • F[C@@]2(C(=O)O)[C@H]3[C@@](C(=O)O)(N)[C@H](OCc1ccc(Cl)c(Cl)c1)C[C@@H]23
  • InChI=1S/C15H14Cl2FNO5/c16-8-2-1-6(3-9(8)17)5-24-10-4-7-11(14(7,18)12(20)21)15(10,19)13(22)23/h1-3,7,10-11H,4-5,19H2,(H,20,21)(H,22,23)/t7-,10-,11+,14-,15+/m1/s1 ДаY
  • Key:LFAGGDAZZKUVKO-JAGWWQSPSA-N ДаY

MGS-0039 je lek koji se koristi u naučnim istraživanjima. On deluje kao potentan i selektivan antagonist grupe II metabotropnih glutamatnih receptora (mGluR2/3).[1][2] On proizvodi antidepresivne i anksiolitičke efekte u životinjskim studijama,[3][4][5][6] i pokazano je da pojačava otpuštanje dopamina i serotonina u specifičnim oblastima mozga.[7][8] Istraživanja pokazuju da do toga može doći sličnim mehanizmom kao i kod srodnog glutaminergičnog leka ketamina.[9][10]

  1. ^ Chaki S, Yoshikawa R, Hirota S, Shimazaki T, Maeda M, Kawashima N, Yoshimizu T, Yasuhara A, Sakagami K, Okuyama S, Nakanishi S, Nakazato A. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology. 2004 Mar;46(4):457-67. PMID 14975669
  2. ^ Nakazato A, Sakagami K, Yasuhara A, Ohta H, Yoshikawa R, Itoh M, Nakamura M, Chaki S. Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. Journal of Medicinal Chemistry. 2004 Aug 26;47(18):4570-87. PMID 15317467
  3. ^ Shimazaki T, Iijima M, Chaki S. Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test. European Journal of Pharmacology. 2004 Oct 6;501(1-3):121-5. PMID 15464070
  4. ^ Yasuhara A, Nakamura M, Sakagami K, Shimazaki T, Yoshikawa R, Chaki S, Ohta H, Nakazato A. Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential. Bioorganic and Medicinal Chemistry. 2006 Jun 15;14(12):4193-207. PMID 16487713
  5. ^ Yoshimizu T, Shimazaki T, Ito A, Chaki S. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berlin). 2006 Jul;186(4):587-93. PMID 16612616
  6. ^ Stachowicz K, Wierońska J, Domin H, Chaki S, Pilc A. Anxiolytic-like activity of MGS0039, a selective group II mGlu receptor antagonist, is serotonin- and GABA-dependent. Pharmacological Reports. 2011;63(4):880-7. PMID 22001975
  7. ^ Kawashima N, Karasawa J, Shimazaki T, Chaki S, Okuyama S, Yasuhara A, Nakazato A. Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors. Neuroscience Letters. 2005 Apr 22;378(3):131-4. PMID 15781145
  8. ^ Karasawa J, Yoshimizu T, Chaki S. A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell. Neuroscience Letters. 2006 Jan 30;393(2-3):127-30. PMID 16233956
  9. ^ Pałucha-Poniewiera A, Wierońska JM, Brański P, Stachowicz K, Chaki S, Pilc A. On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039. Psychopharmacology (Berlin). 2010 Dec;212(4):523-35. PMID 20703449
  10. ^ Koike H, Iijima M, Chaki S. Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists. Neuropharmacology. 2011 Dec;61(8):1419-23. PMID 21903115

Spoljašnje veze

[уреди | уреди извор]